indazoles has been researched along with Cancer of Cervix in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Azaïs, H; Bats, AS; Bentivegna, E; Blons, H; Delanoy, N; Durdux, C; Koual, M; Laurent-Puig, P; Le Frère-Belda, MA; Le Gac, M; Nguyen-Xuan, HT; Perkins, G | 1 |
| Frumovitz, M; Plante, M; St-Gelais, J; Touhami, O | 1 |
| Anakura, M; Ando, K; Darwis, NDM; Hirakawa, T; Hirota, Y; Irie, D; Iwase, A; Kakoti, S; Kaminuma, T; Kumazawa, T; Matsui, T; Murata, K; Nachankar, A; Nakano, T; Noda, SE; Ohno, T; Oike, T; Okonogi, N; Sasaki, Y; Shiba, S; Shibata, A; Tamaki, T; Tokino, T; Yamashita, S | 1 |
| Bharathan, R; Chuai, Y; Dai, G; Li, Y; Otter, SJ; Rizzuto, I; Stewart, A; Wang, A; Zhang, X | 1 |
| Chen, J; Ding, M; Gao, Y; Li, Z; Shi, L; Wang, C; Xu, D; Zhang, H | 1 |
| Alber, JA; Ding, J; Mas Lopez, L; Monk, BJ; Oaknin, A; Pandite, LN; Stutts, MW; Tarpin, C; Termrungruanglert, W; Zarba, JJ | 1 |
| Cho, YS; Chun, YS; Kim, J; Kim, MS; Lee, JC; Park, JW; Yeo, EJ | 1 |
2 review(s) available for indazoles and Cancer of Cervix
| Article | Year |
|---|---|
[Place of PARP inhibitors in the treatment of endometrial and cervical cancers].
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Clinical Trials as Topic; DNA Damage; DNA Repair-Deficiency Disorders; Endometrial Neoplasms; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Papillomavirus Infections; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Uterine Cervical Neoplasms | 2022 |
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Bias; Brachytherapy; Combined Modality Therapy; Confidence Intervals; Female; Gastric Fistula; Gastrointestinal Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Fistula; Intestinal Perforation; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Pyridines; Pyrimidines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Thromboembolism; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Young Adult | 2021 |
1 trial(s) available for indazoles and Cancer of Cervix
| Article | Year |
|---|---|
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Delivery Systems; Female; Humans; Indazoles; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence; Retreatment; Sulfonamides; Uterine Cervical Neoplasms | 2010 |
4 other study(ies) available for indazoles and Cancer of Cervix
| Article | Year |
|---|---|
Association of nivolumab and niraparib in the management of neuroendocrine cancer of the cervix.
Topics: Carcinoma, Neuroendocrine; Cervix Uteri; Female; Humans; Indazoles; Nivolumab; Uterine Cervical Neoplasms | 2023 |
FGFR Signaling as a Candidate Therapeutic Target for Cancers Resistant to Carbon Ion Radiotherapy.
Topics: A549 Cells; Carcinoma, Squamous Cell; Female; Gene Ontology; Heavy Ion Radiotherapy; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Receptor, Fibroblast Growth Factor, Type 3; Receptor, Fibroblast Growth Factor, Type 4; Signal Transduction; Uterine Cervical Neoplasms | 2019 |
The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.
Topics: Animals; Cadherins; Carcinogenesis; Cell Movement; Cell Proliferation; Enhancer of Zeste Homolog 2 Protein; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Indazoles; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Polycomb Repressive Complex 2; Pyridones; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2015 |
YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Hepatocellular; Cell Hypoxia; Culture Media, Conditioned; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Female; G(M1) Ganglioside; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Indazoles; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lymphokines; Male; Mice; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Neuroblastoma; Platelet Endothelial Cell Adhesion Molecule-1; Precipitin Tests; Rats; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Transcription Factors; Transplantation, Heterologous; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |